SNDX — Syndax Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.44bn
- $1.33bn
- $23.68m
Annual cashflow statement for Syndax Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -73.2 | 24.9 | -149 | -209 | -319 |
| Depreciation | |||||
| Non-Cash Items | 9.74 | 13.8 | 14 | 16.9 | 30.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.93 | -9.6 | 1.66 | 31.9 | 13.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -71.3 | 29.1 | -134 | -161 | -275 |
| Capital Expenditures | — | -0.129 | 0 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -143 | -40.7 | -186 | 118 | -220 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -143 | -40.9 | -186 | 118 | -220 |
| Financing Cash Flow Items | 0.001 | 25.4 | 0 | 0 | 344 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 304 | 118 | 172 | 264 | 353 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 90.6 | 107 | -148 | 221 | -141 |